

China Biologic Products, Inc.
Form 8-K
August 09, 2012

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest event Reported): August 7, 2012

CHINA BIOLOGIC PRODUCTS, INC.

(Exact name of registrant as specified in its charter)

Delaware
*(State or other jurisdiction of
incorporation or organization)*

001-34566
(Commission File No.)

75-2308816
(IRS Employer ID No.)

**18th Floor, Jialong International Building
19 Chaoyang Park Road
Chaoyang District, Beijing 100125
People's Republic of China**
(Address of Principal Executive Offices)

86-10-6698-3166
Registrant's telephone number, including area code

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))
-

ITEM 5.02. DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS.

As previously disclosed, each of Mr. Chong Yang Li and Ms. Sandy (Han) Zhang received a greater number of votes withheld from his/her election than votes for such election (a Majority Withheld Vote) at the annual stockholder meeting held on July 20, 2012 (the Annual Meeting) of China Biologic Products, Inc. (the Company). Pursuant to the Company's Corporate Governance Guidelines, any nominee for director who receives a Majority Withheld Vote is obligated to tender his/her resignation to the Board of Directors (the Board). Ms. Zhang and Mr. Li therefore tendered their resignations after the Annual Meeting solely to comply with the Company's Corporate Governance Guidelines. Upon the recommendation of the Governance and Nominating Committee, the Board accepted Mr. Li's and Ms. Zhang's resignations on August 7, 2012 with immediate effect. On the same date, the Board appointed Mr. Albert (Wai Keung) Yeung as a member of the Audit Committee to fill the vacancy resulted from Ms. Zhang's resignation, effective immediately.

On August 7, 2012, the Board also appointed Mr. Ming Yang, the Company's interim Chief Financial Officer, as the Company's Chief Financial Officer, effective immediately. Mr. Yang joined the Company on March 30, 2012 and has been serving as the Company's Vice President-Finance & Compliance and Treasurer since then and the Company's interim Chief Financial Officer since May 31, 2012.

There is no family relationship between each of Mr. Albert (Wai Keung) Yeung and Mr. Ming Yang and any other directors or executive officers of the Company. In addition, there has been no transaction, nor is there any currently proposed transaction, between each of Mr. Yeung and Mr. Yang and the Company that would require disclosure under Item 404(a) of Regulation S-K.
